Table 2.
Efficacy for the first-line treatment in patients with mCRC stratified based on the molecular-target agent and tumour location.
| Left-sided mCRC (n = 76) | Right-sided mCRC (n = 34) | |||||
|---|---|---|---|---|---|---|
| All | Cetuximab (n = 36) | Bevacizumab (n = 40) | All | Cetuximab (n = 14) | Bevacizumab (n = 20) | |
| CR | 3 (4.3%) | 3 (8.3%) | 0 (0.0%) | 1 (2.9%) | 1 (7.1%) | 0 (0.0%) |
| PR | 48* (63.2%) | 25 (69.4%) | 23 (57.5%) | 14* (41.2%) | 4 (28.6%) | 10 (50.0%) |
| SD | 22 (28.9%) | 6 (16.7%) | 16 (40.0%) | 16 (47.1%) | 6 (42.9%) | 10 (50.0%) |
| PD | 3 (3.9%) | 2 (5.6%) | 1 (2.5%) | 3 (8.8%) | 3 (21.4%) | 0 (0.0%) |
| ORR | 51* (67.1%) | 28 (77.8%) | 23 (57.5%) | 15* (44.1%) | 5 (35.7%) | 10 (50%) |
CR complete response, PD progressive disease, PR partial response, RD recommended dose, SD stable disease, ORR overall response.
*p value for difference between tumour side < 0.05.